Intraepidermal squamous cell carcinoma (SCC) is a common superficial form of keratinocyte cancer
Imiquimod is associated with short-term clearance rates of about 80–87% that are sustained for up to 5-years' follow-up
Topical imiquimod and fluorouracil are also treatment options for superficial basal cell carcinoma and squamous cell carcinoma in situ
Imiquimod use produced the following clearance rates: 43% to 100% for superficial BCC
Topical Imiquimod Therapy for Basal and Squamous Cell Carcinomas: A Clinical
Rub it
Imiquimod studies were of treatment of superficial, nodular and infiltrative BCC and
It is typically applied to the skin once or twice a day for several weeks
Imiquimod 5% cream (Aldara) is a novel immune response modifier (IRM) that has been reported as a successful treatment for Bowen's disease in humans
Imiquimod is an agonist for the toll-like receptor 7 and/or 8, inducing a helper T-cell cytokine cascade and interferon production
Photo: Yuri_Arcurs / Getty Images
The molecular basis for imiquimod non-responders, is the Toll-like receptor 7 (TLR7) polymorphism
cSCC in situ or Bowen's disease is defined as a tumor that is limited to the epidermis and has not invaded into the dermis
Imiquimod (ih-mih-kwih-mod) is a prescription medicine that you use at home
1 Topical imiquimod cream has been approved by the Food and Drug Administration for treatment of nonhyperkeratotic actinic keratosis, superficial basal
1 Additionally, topical imiquimod has been reported to be effective for the treatment of selected cases of squamous cell carcinoma in-situ
Estimates on the risk of actinic keratoses progressing to squamous cell carcinomas vary widely
75% cream: Apply a thin film once a day before bedtime to the affected area (either entire face or balding scalp) Comments: Treatment should continue for two 2-week treatment cycles separated by a 2-week no treatment period
Treatment strategies for cutaneous squamous cell carcinoma in situ
Background: Imiquimod 5% cream may provide an effective nonsurgical treatment for superficial basal cell carcinoma (sBCC) based on results of previous studies